1. Aerts A, Eberlein U, Holm S, Hustinx R, Konijnenberg M, Strigari L, van Leeuwen F, Glatting G, Lassmann M. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging in press 23.04.2021
  2. Albrecht J, Exner S, Grotzinger C, Prasad S, Konietschke F, Beindorff N, Kuhl AA, Prasad V, Brenner W, Koziolek EJ. Multimodal Imaging of 2-Cycle PRRT with Lu-177-DOTA-JR11 and Lu-177-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med 2021; 62: 393-8
  3. Alnaalwa B, Nwankwo O, Abo-Madyan Y, Giordano FA, Wenz F, Glatting G. A knowledge-based quantitative approach to characterize treatment plan quality: Application to prostate VMAT planning. Med Phys 2021; 48(1); 94-104.
  4. Attarwala AA, Hardiansyah D, Romanó C, Jiménez-Franco LD, Roscher M, Wängler B, Glatting G. Performance assessment of the ALBIRA II pre-clinical SPECT S102 system for 99mTc imaging. Ann Nucl Med 2021; 35(1): 111-120.
  5. Begum NJ, Glatting G, Eiber M, Beer AJ, Kletting P. An in silico study on the effect of the radionuclide half-life on PET/CT imaging with PSMA-targeting radioligands. Nuklearmedizin 2021; 60(1): 33-37.
  6. Bottke, D., J. Miksch, R. Thamm, T. Krohn, D. Bartkowiak, M. Beer, C. Bolenz, A. J. Beer, V. Prasad and T. Wiegel (2021). "Changes of Radiation Treatment Concept Based on (68)Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy." Front Oncol 11: 665304.
  7. Brenner, W., J. Strobel, and V. Prasad, PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities? Journal of Nuclear Medicine, 2021. 62(9): p. 1242-1243.
  8. Eberhardt, N. and Prasad V., 68 Ga-FAPI-PET/CT verändert die Behandlungsstrategie bei Karzinomen des unteren Gastrointestinaltrakts. RöFo, 2021. 193(06): p. 632-633.
  9. Ettrich TJ, Hüttner FJ, Lisson C, Gani C, Prasad V, Seufferlein T. Hepatisch metastasiertes kolorektales Karzinom [Multimodal, interdisciplinary therapeutic concepts for liver metastasized colorectal cancer]. Dtsch Med Wochenschr. 2021 Nov;146(22):1468-1477. German. doi: 10.1055/a-1391-5273. Epub 2021 Nov 5.
  10. Exner S, Arrey G, Prasad V, Grötzinger C. mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms. Front Oncol 2021; 10: 578380
  11. Grunert, M., N. Eberhardt, V. Prasad and A. J. Beer (2021). "Nuklearmedizinische Diagnostik und Therapie des Prostatakarzinoms." Journal für Urologie und Urogynäkologie/Österreich 28(2): 58-72.
  12. Hardiansyah D, Kletting P, Begum NJ, Eiber M, Beer AJ, Pawiro SA, Glatting G. Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: A global sensitivity analysis for a physiologically-based pharmacokinetic model. Med Phys 2021; 48(2): 556-568.
  13. Hardiansyah D, Riana A, Kletting P, Zaid NRR, Eiber M, Pawiro SA, Beer AJ, Glatting G. A population-based method to determine the time-integrated activity in molecular radiotherapy. EJNMMI Phys 2021; 8: 82.
  14. Hicks, R., C. Dromain, W. W. de Herder, F. Costa, C. M. Deroose, A. Frilling, A. Koumarianou, E. Krenning, E. Raymond, L. Bodei, H. Sorbye, S. Welin, B. Wiedenmann, D. Wild, J. Howe, J. Yao, D. O’Toole, A. Sundin and V. Prasad (2021). "ENETS consensus guidance for synoptic reporting of molecular imaging studies." Journal of Neuroendocrinology n/a(n/a): e13040.
  15. Jiménez-Franco LD, Glatting G, Prasad V, Weber WA, Beer AJ, Kletting P. Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: An in silico analysis for standard and optimized treatment. J Nucl Med 2021; 62: 92-96.
  16. Kattner P, Zeiler K, Herbener VJ, La Ferla-Bruhl K, Kassubek R, Grunert M, Burster T, Bruhl O, Weber AS, Strobel H, Karpel-Massler G, Ott S, Hagedorn A, Tews D, Schulz A, Prasad V, Siegelin MD, Nonnenmacher L, Fischer-Posovszky P, Halatsch ME, Debatin KM, Westhoff MA. What Animal Cancers teach us about Human Biology. Theranostics 2021; 11: 6682-702
  17. Kersten, J., N. Eberhardt, V. Prasad, M. Keßler, S. Markovic, J. Mörike, N. Nita, T. Stephan, M. Tadic, T. Tesfay, W. Rottbauer and D. Buckert (2021). "Non-invasive Imaging in Patients With Chronic Total Occlusions of the Coronary Arteries-What Does the Interventionalist Need for Success?" Front Cardiovasc Med 8: 713625.
  18. Kossatz S, Beer AJ, Notni J. It's Time to Shift the Paradigm: Translation and Clinical Application of Non-alpha v beta 3 Integrin Targeting Radiopharmaceuticals. Cancers 2021; 13: 18
  19. Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Buetof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Loeck S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Poettgen C, Roedel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zoephel K, Zschaeck S, Thorwarth D, Troost EGC. Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie 2021; 197: 757-79
  20. Löffler J, Hamp C, Scheidhauer E, Di Carlo D, Solbach C, Abaei A, Hao L, Glatting G, Beer AJ, Rasche V, Winter G. Comparison of Quantification of Target-Specific Accumulation of F-18 F-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI. Cancers 2021; 13: 24
  21. Makowski MR, Rischpler C, Ebersberger U, Keithahn A, Kasel M, Hoffmann E, Rassaf T, Kessler H, Wester HJ, Nekolla SG, Schwaiger M, Beer AJ. Multiparametric PET and MRI of myocardial damage after myocardial infarction: correlation of integrin alpha v beta 3 expression and myocardial blood flow. Eur J Nucl Med Mol Imaging epub 24.09.2020: 11.
  22. Patt M, Kuwert T, Luster M, Krause BJ, Solbach C. Regulatorische Anforderungen an Radiopharmaka in Deutschland: die Fachgesellschaft im behördlichen Dialog. Nuklearmedizin 2021; 60: 55-8.
  23. Patt M, Schulze R, Breitkreutz F, Vogg A, Solbach C. Zum Rechtsstatus von Kits in der Herstellung von Radiopharmaka. Nuklearmedizin 2021; 60: 115-20.
  24. Prasad, V., K. Huang, S. Prasad, M. R. Makowski, N. Czech and W. Brenner (2021). "In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2(nd) Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With (177)Lu-PSMA." Front Oncol 11: 578093.
  25. Prasad V, Prasad S, Lehnert W, Brenner W, Kai H, Bronzel M, Kluge A. Effect of peptide dose on radiation dosimetry for peptide receptor radionuclide therapy with Lu-177-DOTATOC: A pilot study. Indian J Nucl Med 2021; 36: 412-21.
  26. Prasad V, Zengerling F, Steinacker JP, Bolenz C, Beer M, Wiegel T, Eiber M, Fleshner N, Beer AJ. First Experiences with Lu-177-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients. J Nucl Med 2021; 62: 975-9.
  27. Puranik, A. D., C. Dromain, N. Fleshner, M. Sathekge, M. Pavel, N. Eberhardt, F. Zengerling, R. Marienfeld, M. Grunert and V. Prasad (2021). "Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer." Cancers (Basel) 13(14).
  28. Schaal MC, Gendler L, Ammann B, Eberhardt N, Janda A, Morbach H, Darge K, Girschick H, Beer M. Imaging in non-bacterial osteomyelitis in children and adolescents: diagnosis, differential diagnosis and follow-up-an educational review based on a literature survey and own clinical experiences. Insights Imaging 2021; 12: 14.
  29. Schmidt-Hegemann, N.-S., C. Zamboglou, R. Thamm, C. Eze, S. Kirste, S. Spohn, M. Li, C. Stief, C. Bolenz, W. Schultze-Seemann, P. Bartenstein, V. Prasad, U. Ganswindt, A.-L. Grosu, C. Belka, B. Mayer and T. Wiegel (2021). "A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa." Frontiers in Oncology 11(3991).
  30. Spogis J, Hagen F, Thaiss WM, Hoffmann T, Malek N, Nikolaou K, Berg CP, Singer S, Bosmuller H, Kreth F, Kaufmann S. Sonographic findings in coronavirus disease-19 associated liver damage. Plos One 2021; 16: 12.
  31. Steiger K, Quigley NG, Groll T, Richter F, Zierke MA, Beer AJ, Weichert W, Schwaiger M, Kossatz S, Notni J. There is a world beyond alpha v beta 3-integrin: Multimeric ligands for imaging of the integrin subtypes alpha v beta 6, alpha v beta 8, alpha v beta 3, and alpha 5 beta 1 by positron emission tomography. Ejnmmi Research 2021; 11: 14.
  32. Steinacker JP, Steinacker-Stanescu N, Ettrich T, Kornmann M, Kneer K, Beer A, Beer M, Schmidt SA. Computed Tomography-Based Tumor Heterogeneity Analysis Reveals Differences in a Cohort with Advanced Pancreatic Carcinoma under Palliative Chemotherapy. Visc Med 2021; 37: 77-83.
  33. Surov A, Schmidt SA, Prasad V, Beer AJ, Wienke A. FDG PET correlates weakly with HIF-1  expression in solid tumors: a meta-analysis. Acta Radiol epub 19.06.2020: 8.
  34. Thaiss WM, Gatidis S, Sartorius T, Machann J, Peter A, Eigentler TK, Nikolaou K, Pichler BJ, Kneilling M. Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients. Cancer Immunol Immunother epub 01.11.2020: 13.
  35. Yousefzadeh-Nowshahr E, Winter G, Bohn P, Kneer K, von Arnim CAF, Otto M, Solbach C, Anderl-Straub S, Polivka D, Fissler P, Prasad V, Kletting P, Riepe MW, Higuchi M, Ludolph A, Beer AJ, Glatting G. Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. Z Med Phys. 2021; 31(1): 37-47.
  36. Zaid NRR, Kletting P, Winter G, Prasad V, Beer AJ, Glatting G. A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice. Pharmaceutics 2021; 13: 2132.